XUE [Xueda Education] UPLOAD: (Original Filing)
[]
CO [Chinard Bloodrp] 6-K: (Original Filing)
[EXECUTION VERSION CHINARD BLOODRPORATION 7% SENIORNVERTIBLE NOTE Original Principal Amount: US$50,000,000mpany Holder Principal and Issuancete and Note Notes Other Notes Registration Rightsreement FOR VALUE RECEIVED, Chinard Bloodrporation, an exemptedmpany with limited liabilityorporated in theyman Islands (the 1. Rank pari passu] [EXECUTION VERSION REGISTRATION RIGHTSREEMENT between CHINARD BLOODRPORATION and GOLDEN MEDITECHS LIMITEDted October 3, 2012 TABLE OFNTENTS Page Section 1 DEFINITIONS 1 Section 2 GENERAL; SECURITIES SUBJECT TO THISREEMENT 5 Section 3 MANDATORY REGISTRATION 5 Section 4 DEMAND REGISTRATION RIGHTS 8 Section 5IDENTAL OR PIGGY-BACK REGISTRATION] [Chinard Bloodrporation Announcesmpletion of $50 Millionnvertible Note Financing with Golden Meditech HONG KONG, China, October 3, 2012 Chinard Bloodrporation (NYSE:) (CCBC or thempany), the first and largestrd blood banking operator in China, announced that it has successfullympleted the previously announced The board of directors of CCBC has appointed Mr. Yuen Kam, currently the Chairman and]
CO [Chinard Bloodrp] 6-K: EXECUTION VERSION CHINARD BLOODRPORATION 7% SENIORNVERTIBLE NOTE Original
[EXECUTION VERSION CHINARD BLOODRPORATION 7% SENIORNVERTIBLE NOTE Original Principal Amount: US$50,000,000mpany Holder Principal and Issuancete and Note Notes Other Notes Registration Rightsreement FOR VALUE RECEIVED, Chinard Bloodrporation, an exemptedmpany with limited liabilityorporated in theyman Islands (the 1. Rank pari passu] [EXECUTION VERSION REGISTRATION RIGHTSREEMENT between CHINARD BLOODRPORATION and GOLDEN MEDITECHS LIMITEDted October 3, 2012 TABLE OFNTENTS Page Section 1 DEFINITIONS 1 Section 2 GENERAL; SECURITIES SUBJECT TO THISREEMENT 5 Section 3 MANDATORY REGISTRATION 5 Section 4 DEMAND REGISTRATION RIGHTS 8 Section 5IDENTAL OR PIGGY-BACK REGISTRATION] [Chinard Bloodrporation Announcesmpletion of $50 Millionnvertible Note Financing with Golden Meditech HONG KONG, China, October 3, 2012 Chinard Bloodrporation (NYSE:) (CCBC or thempany), the first and largestrd blood banking operator in China, announced that it has successfullympleted the previously announced The board of directors of CCBC has appointed Mr. Yuen Kam, currently the Chairman and]
OIIM [O2MICRO INTERNATIONAL] 6-K: (Original Filing)
[O2Micro Revises Third Quarter 2012 Financial Guidance 2 GEORGE TOWN, Grandyman, Oct. 3, 2012 (GLOBE NEWSWIRE) -- O The reduction in anticipated revenue for the third quarter is primarily the result of broad-based weakness in demand in thempany's end markets. 2 2 2 Sterling Du, Chairman and CEO of O]
TPI [TIANYIN PHARMACEUTICAL] 8-K: (Original Filing)
[TPI Reports Fiscal Year 2012 Financial Results CHENGDU, China, September 28, 2012 Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for the fiscal year 2012. Fiscal Year 2012 Ended June 30, 2012 Financial Highlights: ● FY2012 revenue delivered] [Tianyin Pharmaceutical Co., Inc. Fiscal 2012 Earnings Call September 28, 2012 Operator: I would now like to turn the conference over to our host, Dr. James Tong, Chief Financial Officer. Please go ahead, sir. Dr. James Tong: Fiscal year 2012 financial highlights. Revenue delivered $69.6 million, compared with $95.2 million in fiscal year 2011. Operating income delivered $8.5 million, compared] [CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K CURRENT REPORT September 28, 2012 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction of incorporation) (IRS Employer Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8615-4737 o o o]
OIIM [O2MICRO INTERNATIONAL] 6-K: O2Micro Revises Third Quarter 2012 Financial Guidance 2
[O2Micro Revises Third Quarter 2012 Financial Guidance 2 GEORGE TOWN, Grandyman, Oct. 3, 2012 (GLOBE NEWSWIRE) -- O The reduction in anticipated revenue for the third quarter is primarily the result of broad-based weakness in demand in thempany's end markets. 2 2 2 Sterling Du, Chairman and CEO of O]
